Literature DB >> 11470547

Molecular characterization of the pore-forming toxin, pyolysin, a major virulence determinant of Arcanobacterium pyogenes.

S J Billington1, J G Songer, B H Jost.   

Abstract

Arcanobacterium pyogenes is a common inhabitant and opportunistic pathogen of domestic animals. The pathogenesis of this organism in a range of suppurative diseases is not well understood. However, the development of genetic techniques to study this organism has allowed advances in the analysis of A. pyogenes virulence factors. A major step in this analysis was the identification and cloning of the A. pyogenes hemolytic exotoxin, pyolysin (PLO). PLO is the most divergent member of the cholesterol-binding pore-forming family of toxins. PLO is also divergent in a C-terminal undecapeptide motif which is almost invariant among other members of the family. This divergent undecapeptide motif is required for the full cytolytic activity of PLO and is also responsible for its oxygen-resistant nature. Insertional inactivation of the plo gene results in a significant reduction in virulence in an intraperitoneal mouse model of infection. The virulence of the plo mutant can be restored by providing PLO in trans, suggesting that PLO is a major virulence factor in A. pyogenes pathogenesis in mice. Results of previous vaccination trials with crude antigens against A. pyogenes infection in domestic animals and mice have been equivocal at best. However, a recombinant PLO-based subunit vaccine protected mice from experimental A. pyogenes infection, indicating that PLO is also an important host protective antigen. These results provide promise that the dogma that domestic animals are recalcitrant to vaccination against A. pyogenes infection may prove false.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470547     DOI: 10.1016/s0378-1135(01)00373-x

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Inerolysin, a cholesterol-dependent cytolysin produced by Lactobacillus iners.

Authors:  Ryan Rampersaud; Paul J Planet; Tara M Randis; Ritwij Kulkarni; Jorge L Aguilar; Robert I Lehrer; Adam J Ratner
Journal:  J Bacteriol       Date:  2010-12-17       Impact factor: 3.490

2.  Heterologous Prime-Boost Immunization with DNA Vaccine and Modified Recombinant Proteins Enhances Immune Response against Trueperella pyogenes in Mice.

Authors:  Ting Huang; Kelei Zhao; Xuhao Song; Tao Song; Xinrong Wang; Xiuyue Zhang; Bisong Yue; Yiwen Chu
Journal:  Vaccines (Basel)       Date:  2022-05-25

3.  Characterization of anthrolysin O, the Bacillus anthracis cholesterol-dependent cytolysin.

Authors:  Jeffrey G Shannon; Cana L Ross; Theresa M Koehler; Richard F Rest
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

4.  Trueperella pyogenes pyolysin inhibits lipopolysaccharide-induced inflammatory response in endometrium stromal cells via autophagy- and ATF6-dependent mechanism.

Authors:  Maozhen Qi; Jianguo Liu; Qingran Jiang; Hongyu Niu; Xinyu Wang; Dong Zhou; Pengfei Lin; Huatao Chen; Aihua Wang; Yaping Jin
Journal:  Braz J Microbiol       Date:  2021-01-16       Impact factor: 2.476

5.  Draft Genome Sequence of Trueperella pyogenes, Isolated from the Infected Uterus of a Postpartum Cow with Metritis.

Authors:  Robert J Goldstone; Matt Amos; Richard Talbot; Hans-Joachim Schuberth; Olivier Sandra; I Martin Sheldon; David G E Smith
Journal:  Genome Announc       Date:  2014-04-24

6.  Cognitive deficits caused by a disease-mutation in the α3 Na(+)/K(+)-ATPase isoform.

Authors:  Thomas Hellesøe Holm; Toke Jost Isaksen; Simon Glerup; Anders Heuck; Pernille Bøttger; Ernst-Martin Füchtbauer; Steen Nedergaard; Jens Randel Nyengaard; Mogens Andreasen; Poul Nissen; Karin Lykke-Hartmann
Journal:  Sci Rep       Date:  2016-08-23       Impact factor: 4.379

7.  Inhibiting mevalonate pathway enzymes increases stromal cell resilience to a cholesterol-dependent cytolysin.

Authors:  Sholeem Griffin; Giulio Preta; Iain Martin Sheldon
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.